<?xml version="1.0" encoding="UTF-8"?>
<p>Mechanisms are in place to ensure continuous collaboration and multilateral exchange of information among international regulators from the initial notification and throughout all the stages of the assessment of the issue, until its resolution. For instance, whenever an issue discussed at IRN is deemed to be of relevance internationally, the outcomes of the discussion, together with relevant documents are promptly shared with international regulators with whom confidentiality agreements are in place. For issues of major public health impact new ad‐hoc confidentiality agreements and collaborations may be set‐up, as has happened for example, in response to the nitrosamine contamination. Additionally, strategic partnerships across the regions, usually referred to as “clusters,” have been established, with experts from the EMA and other RAs who meet periodically via teleconference.
 <xref rid="pds5133-bib-0017" ref-type="ref">
  <sup>17</sup>
 </xref> For instance, the pharmacovigilance cluster offers the opportunity to promptly share information on drug safety issues, including product‐related risk assessment (especially if emerging safety concern) and to provide advance notice on anticipated regulatory actions, public information, and communication prior to decision making and publication.
 <xref rid="pds5133-bib-0018" ref-type="ref">
  <sup>18</sup>
 </xref>
</p>
